Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today ...
A UCLA-led team has developed a machine-learning model that can predict with a high degree of accuracy the short-term survival of dialysis patients on Continuous Renal Replacement Therapy (CRRT). CRRT ...
Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes ...
In January 2025, SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI ...
A SOFA score of 12 or higher at ICU admission is associated with an increased risk for hospital mortality among critically ill patients with COVID-19 and AKI requiring CRRT. The Sequential Organ ...
SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
(RTTNews) - Specialty pharmaceutical company Talphera, Inc. (TLPH), Monday announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously ...
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst ...
The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results